India Pharma Outlook Team | Thursday, 19 June 2025
Welcure Drugs & Pharmaceuticals announced on Wednesday that it has finalized a contract with Thailand-based Fortune Sagar Impex Compamy for third-party sourcing and procurement services totaling Rs 517 cr.
In an exchange filing, Welcure Drugs & Pharmaceuticals Ltd said that it would source and purchase certain finished-dosage SKUs.According to the filing, the business, which is built on a fee-based model, will get a set 5% commission on the cost of goods. For FY 2025-2026, an estimated Rs 25.85 cr in service income is anticipated, which will significantly increase Welcure's revenue. According to the filing, Welcure has a high-margin growth opportunity as a result of the mandate, which strengthens its fee-based portfolio without adding to its balance-sheet risk. Packaging, labeling, containerization, insurance, freight, and all destination- country regulatory clearances will fall within the purview of the Thailand- based company. Following the announcement, the company's shares increased by 5% to reach the highest level at Rs 13.74
Also Read: Ardena Expands with Acquisition of Catalent's Drug Manufacturing Site
A variety of pharmaceutical formulations are produced and marketed by the Indian pharmaceutical company Welcure Drugs & Pharmaceuticals Ltd. On June 4, 1992, the corporation was incorporated. Their product portfolio includes various drug categories like antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, and anti diabetics. Additionally, they manufacture and distribute medications as liquid orals, dry syrups, pills, and capsules.
